Lipids & metabolic liver disease
Joint association of remnant cholesterol and lipoprotein‐associated phospholipase A2 with composite adverse events: A 12‐year follow‐up study from Asymptomatic Polyvascular Abnormalities Community study
Main finding · Composite endpointResult — go to the resultHazard ratio 1.43 95% CI 1.07–1.91Authors' conclusion
Elevated RC and Lp-PLA2 levels were associated with an increased risk of composite adverse events, with these associations significantly influenced by sex and age. Our study highlights the synergistic effect of RC and Lp-PLA2 on the composite adverse events.
Study context
- Population
- Asymptomatic Polyvascular Abnormalities Community study participants, 2010–2022; mean age 60.6 years, 74.3% maleeligible
- Participants
- 1,864 participants
- Exposure
- Joint remnant cholesterol (RC) and Lp-PLA2 categories vs low-RC/Lp-PLA2-
- Outcome
- Composite of:
- First-ever stroke
- MI
- All-cause mortality
- Follow-up
- 12 years
Methodological detailscommunity-based, 12-year follow-up
- Community-based
- 12-year follow-up
Main finding
Composite endpoint
Hazard ratio
1.43
95% CI 1.07–1.91
high-RC/Lp-PLA2+vs low-RC/Lp-PLA2-
HR 1.43 (95% CI 1.07–1.91)
As reported in the abstract
- Composite adverse events identified
- 500
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| Strokehigh-RC/Lp-PLA2+vs low-RC/Lp-PLA2- | 1.37 (0.87–2.16) | |
| MIhigh-RC/Lp-PLA2+vs low-RC/Lp-PLA2- | 0.72 (0.28–1.82) | |
| MACEhigh-RC/Lp-PLA2+vs low-RC/Lp-PLA2- | 1.29 (0.85–1.95) | |
| All-cause deathhigh-RC/Lp-PLA2+vs low-RC/Lp-PLA2- | 1.61 (1.10–2.38) | |
| 0.20.5125Hazard ratio (log scale) |
- MACE — MACE identified
- 210
- All-cause death — All-cause deaths identified
- 342
- All-cause death — Joint association modified by sex (p for interaction)
- 0.035
- All-cause death — Joint association modified by age <60 vs ≥60 years (p for interaction)
- 0.01
All-cause death
- Significant RC × Lp-PLA2 interaction for all-cause death (p for interaction <0.05)
Original publication
Joint association of remnant cholesterol and lipoprotein‐associated phospholipase A2 with composite adverse events: A 12‐year follow‐up study from Asymptomatic Polyvascular Abnormalities Community study. Diabetes Obes Metab. Published 4 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →